Research use only. Nothing on this page is medical advice.
None of these five peptides is approved to heal anything. Here they are, ranked by how much evidence each one has.
- BPC-157: 35 animal studies and 1 human study in one systematic review (1).
- TB-500: in the one rat test that ran it next to BPC-157, TB-500 reached significance on tendon strength and BPC-157 didn’t (2).
- GHK-Cu: human trials exist, but for skin and wrinkles (3).
- KPV and AHK-Cu: mostly lab work (4, 5).
Jump to the ranking, BPC-157, TB-500, legal status or buying guides.
The 5 healing peptides, ranked
How to read the table. Animals: studies in rodents or other animals. Limited: small human data. Dish: lab work on cells or tissue.
| Peptide | Strongest evidence | Human evidence | Main limit |
|---|---|---|---|
| 1BPC-157 | AnimalsRat studies across tendon, ligament, muscle, bone and skin. 35 of the 36 studies in one systematic review were animal or lab studies (1) | One retrospective series (doctors reviewing past cases): 7 of 12 people with chronic knee pain reported relief for over 6 months. Three uncontrolled pilots in all, under 30 people (1, 6) | More than 80% of the studies come from one Zagreb group (6) |
| 2TB-500 and TB-4 | AnimalsAn 80-study scoping review. In one rat Achilles test, TB-500 reached significance on load to failure and BPC-157 didn’t (2, 7) | Human evidence sits in eye and skin settings. Direct TB-500 evidence is a single study (7) | The head-to-head used 32 rats |
| 3GHK-Cu | LimitedReviews report more fibroblast migration, collagen and elastin, and wound closure with GHK formulations (4) | Skin trials only. A 40-person trial cut wrinkle volume 55.8% against a control serum (3). No clinical data for muscle, tendon or joint conditions (8) | Skin results may not carry over to tendons |
| 4KPV | AnimalsKPV hydrogels reduced inflammation, promoted regeneration and fought MRSA in lab work (4) | None found for healing | An anti-inflammatory signal, not a repair result |
| 5AHK-Cu | DishStimulated human hair follicle growth and dermal papilla cell growth in lab dishes (5) | None for healing | Its one study is about hair, not wounds |
BPC-157: 35 animal studies, 1 human study
BPC-157 has the most research of the five. Almost all of it is in animals.
- In animals it activates VEGFR2 (a blood vessel growth receptor) and nitric oxide signaling, which promotes new blood vessels and wakes up fibroblasts (9).
- Rodent studies report faster healing of deep burns, diabetic ulcers and alkali burns (10).
- A rat study of quadriceps muscle torn off the bone reported better walking and less leg contracture with oral BPC-157 (11).
In people, the data is one retrospective series and three small pilots, with fewer than 30 people in total. None used a standard pharmaceutical preparation (1, 6). No clinical safety data exists (1).
Its plasma half-life, the time for half of it to leave your blood, is under 30 minutes (1). It has no approved formulation, no validated dose and no completed phase II trial (6). Most of the studies come from one group, so independent labs haven’t confirmed them (6).
Read our BPC-157 vs TB-500 and peptides for tendon repair guides for the tendon detail.
TB-500: the one head-to-head
Thymosin beta-4 (TB-4) is a peptide your body makes. TB-500 is a synthetic version sold online. Most of the research is on TB-4, and only one study in the scoping review tested TB-500 directly (7).
The rat Achilles study is the one direct comparison. It had 32 rats in four groups, treated for four weeks (2).
- TB-500 reached significance on tendon strength, measured as maximum load before failure (P < .05).
- TB-500 also scored significantly better on two tendon health scores (Bonar P = .016, Movin P = .017).
- BPC-157 improved some measures but not to significance.
- Giving both gave no extra benefit over either alone (2).
It is a small, exploratory rat study, so it doesn’t show TB-500 beats BPC-157 in people. More in our TB-500 guide and the BPC-157 plus TB-500 research.
GHK-Cu, KPV and AHK-Cu
These three are tripeptides. Their healing evidence is thinner.
- GHK-Cu has human skin trials, and one review found 20 studies, 18 in animals or labs and 2 randomized trials (12). None of them covers tendon, muscle or joint repair (8).
- KPV is an anti-inflammatory peptide. Its healing data comes from lab work with a gel carrier (4). See the KPV guide.
- AHK-Cu ranks last because its one study measured hair follicle growth in dishes and never looked at wounds (5). See the AHK-Cu guide and AHK-Cu vs GHK-Cu.
Are healing peptides legal?
None of the five is FDA-approved.
On 28 October 2026 HHS announced an interim policy. It lets state-licensed pharmacies compound six named peptides on a patient-specific prescription. Three of those are on this list. BPC-157 can be injected, oral or topical, TB-500 is injected, and KPV is topical or oral. It isn’t approval, and it excludes products sold as research chemicals or supplements (13). GHK-Cu and AHK-Cu aren’t named.
WADA bans BPC-157 under S0 (non-approved substances) and TB-500 under its growth-factor class, so tested athletes can’t use either (14).
Healing peptide dosage and safety
We don’t list doses. Reviews say indications, dosing, frequency and duration are unknown (8).
- Animal safety studies of BPC-157 found no adverse effects across several organ systems, but no clinical safety data exists (1).
- The BPC-157 pilots reported no adverse effects, and they were too small to prove safety (9).
- Unregulated manufacturing raises contamination risk. A purity certificate doesn’t prove a vial is safe to inject (1).
Where to buy healing peptides
Each guide below compares sellers by what their lab reports show.
Match the lot number on any vial to its report. Our guide to verifying a peptide COA shows how. For the wider ranking, see best peptides by goal, peptides for joint pain and best peptide vendors. For injuries, see best peptides for injury recovery, and for nerve damage see ARA-290.
Healing peptides FAQ
What is the best peptide for healing?
No peptide is proven. BPC-157 has the most animal research, with 35 animal studies to 1 human study in one review. TB-500 reached significance where BPC-157 didn’t in one rat tendon test. GHK-Cu has human trials, but for skin.
Does BPC-157 heal tendons?
In rats, yes in many studies. In people, no controlled trial exists. The human data is one retrospective knee-pain series and three small pilots.
What is the difference between BPC-157 and TB-500?
BPC-157 is a stomach protein fragment that works through VEGFR2 and nitric oxide. TB-500 is a synthetic version of thymosin beta-4, which regulates actin (a cell scaffold protein) and cell migration. In one rat Achilles study, only TB-500 reached significance on tendon strength.
Can you take BPC-157 orally?
A rat study used oral BPC-157 for torn quadriceps. No human oral healing trial exists. The HHS policy lists oral BPC-157 for pharmacy compounding, with documentation of bioavailability required.
Are BPC-157 and TB-500 FDA approved?
No. HHS announced a policy on 28 October 2026 that lets licensed pharmacies compound both on prescription. It isn’t approval, and it excludes research chemicals.
Are healing peptides banned in sport?
Yes. WADA bans BPC-157 under S0 and TB-500 under its growth-factor class.
How do peptides help the body heal?
In animal and cell studies they grow blood vessels, move repair cells into the wound, build collagen and lower inflammation. Human proof of those effects for injuries is missing.
How long do healing peptides take to work?
No human timeline exists. In the one BPC-157 knee-pain series, 7 of 12 people reported relief lasting over 6 months, but it was retrospective and uncontrolled.
Is AHK-Cu a healing peptide?
Its only study measured hair follicle growth in dishes. No wound or tissue repair data exists for it.
Sources
Show references (14)Hide references
- Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J 2025. Source
- Bicer O, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg 2026. Source
- Badenhorst T, et al. Effects of GHK-Cu on MMP and TIMP expression, collagen and elastin production, and facial wrinkle parameters. J Aging Sci 2016. Source
- Adnan SB, et al. Exploring the role of tripeptides in wound healing and skin regeneration: a comprehensive review. Int J Med Sci 2025. Source
- Pyo HK, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res 2007. Source
- Mateescu DM, et al. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies, and translational barriers. Pharmaceutics 2026. Source
- McGuire F, et al. Thymosin beta-4 and TB-500 in tissue healing, regeneration, and musculoskeletal repair: a scoping review. Appl Sci 2026. Source
- Mayfield CK, et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. Am J Sports Med 2026. Source
- McGuire F, et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med 2025. Source
- Seiwerth S, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Front Pharmacol 2021. Source
- Matek D, et al. Stable gastric pentadecapeptide BPC 157 as therapy after surgical detachment of the quadriceps muscle from its attachment. Pharmaceutics 2025. Source
- Mokhtar J, et al. The regenerative potential of GHK-Cu in aesthetic medicine. Aesthet Surg J 2026. Source
- BakerHostetler. HHS issues enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. 28 October 2026. Source
- WADA. The 2026 Prohibited List, sections S0 and S2. Source
